DrugPatentWatch Database Preview
Apomorphine hydrochloride - Generic Drug Details
What are the generic sources for apomorphine hydrochloride and what is the scope of patent protection?
Apomorphine hydrochloride
is the generic ingredient in one branded drug marketed by Us Worldmeds and is included in one NDA. Additional information is available in the individual branded drug profile pages.There are six drug master file entries for apomorphine hydrochloride. One supplier is listed for this compound.
Summary for apomorphine hydrochloride
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 6 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 48 |
| Clinical Trials: | 38 |
| Patent Applications: | 5,500 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | apomorphine hydrochloride at DailyMed |
Recent Clinical Trials for apomorphine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Western University, Canada | N/A |
| Alexza Pharmaceuticals, Inc. | Phase 1 |
| Rennes University Hospital | N/A |
Pharmacology for apomorphine hydrochloride
| Drug Class | Dopaminergic Agonist |
| Mechanism of Action | Dopamine Agonists |
Medical Subject Heading (MeSH) Categories for apomorphine hydrochloride
Synonyms for apomorphine hydrochloride
| (-)-10,11-Dihydroxyaporphine |
| (-)-Apomorphine |
| (-)-Apomorphine (hydrochloride) |
| (-)-Apomorphine hydrochloride |
| (-)-Apomorphinium hydrochloride |
| (-)6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol(APO) |
| (6aR)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo(de,g)chinolin-10,11-diol |
| (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol |
| (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol hydrochloride |
| (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrate;hydrochloride |
| (9R)-10-methyl-10-azatetracyclo[7.7.1.0^{2,7}.0^{13,17}]heptadeca-1(17),2,4,6,13,15-hexaene-3,4-diol |
| (9R)-10-methyl-10-azatetracyclo[7.7.1.0;{2,7}.0;{13,17}]heptadeca-1(16),2(7),3,5,13(17),14-hexaene-3,4-diol |
| (Apomorphine) 6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol |
| (apomorphine)6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol |
| (R)-(-)-Apomorphine |
| (R)-(-)-apomorphine HCl |
| (R)-(-)-Apomorphine hydrochloride |
| (R)-5,6,6A,7-TETRAHYDRO-6-METHYL-4H-DIBENZO[DE-G]QUINOLINE-10,11-DIOL |
| (R)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol hydrochloride |
| (R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol |
| (R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol ((R)-apomorphine) |
| (R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol (apomorphine) |
| (R)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol hydrochloride |
| (R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol(apomorphine) |
| 314-19-2 |
| 314-19-2 (hydrochloride anhydrous) |
| 372A207 |
| 41372-20-7 |
| 41372-20-7 (hydrochloride hemihydrate) |
| 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (R)- |
| 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (R)- (9CI) |
| 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)- |
| 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (6aR)- |
| 4H-Dibenzo[de,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (R)- |
| 5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo(de,g)chinolin-10,11-diol hydrochlorid |
| 58-00-4 |
| 58-00-4 (Parent) |
| 5896-07-1 |
| 6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol ((R)-apomorphine) |
| 6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol((R)-apomorphine) |
| 6a-beta-Aporphine-10,11-diol |
| 6a-beta-Aporphine-10,11-diol, hydrochloride |
| 6a-beta-Noraporphine-10,11-diol, 6-methyl-, hydrochloride |
| 6a.beta.-Aporphine-10, hydrochloride |
| 6a.beta.-Noraporphine-10, 6-methyl-, hydrochloride |
| 6abeta-Aporphine-10,11-diol |
| 6abeta-Aporphine-10,11-diol, hydrochloride |
| 6abeta-Aporphine-10,11-diol, hydrochloride (8CI) |
| 6abeta-Noraporphine-10,11-diol, 6-methyl-, hydrochloride |
| 8233AH |
| 9K13MD7A0D |
| AC1L1LLC |
| AC1L1SZ7 |
| AC1Q3F8P |
| AKOS024456928 |
| API0001523 |
| Apokyn |
| Apomorfin |
| Apomorphin |
| Apomorphin hydrochlorid |
| apomorphine |
| Apomorphine (BAN) |
| Apomorphine (R,-) |
| Apomorphine [BAN] |
| Apomorphine chloride |
| Apomorphine HCl |
| Apomorphine Hydrochloride (anhydrous) |
| Apomorphine hydrochloride (R,-) |
| Apomorphine hydrochloride anhydrous |
| Apomorphine hydrochloride hemihydrate |
| Apomorphine Hydrochloride, Anhydrous |
| Apomorphine SL |
| apomorphine-hcl |
| APOMORPHINE, HYDROCHLORIDE |
| APOMORPHINE6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol |
| Apomorphinium chloride |
| Apomorphinium chloride hemihydrate |
| Apomorphinum hydrochloricum |
| Apormorphine |
| B6936 |
| BDBM29644 |
| BDBM50001955 |
| BG0043 |
| Biomol-NT_000019 |
| BPBio1_000092 |
| BPBio1_001179 |
| BRD-K76022557-001-01-3 |
| BRD-K76022557-311-20-6 |
| BSPBio_000082 |
| C17H17NO2 |
| C17H17NO2.HCl |
| CAS-58-00-4 |
| CHEBI:48538 |
| CHEMBL1616 |
| CHEMBL53 |
| cid_6852399 |
| CTK8F2000 |
| D07460 |
| DB00714 |
| DSSTox_CID_2614 |
| DSSTox_GSID_22614 |
| DSSTox_RID_76660 |
| DTXSID5040598 |
| DTXSID8022614 |
| EINECS 200-360-0 |
| EINECS 206-243-0 |
| FT-0602881 |
| GTPL33 |
| H72A207 |
| HMS2089C10 |
| HSDB 3289 |
| IV Apomorphine |
| Ixense |
| J-018414 |
| L-Apomorphine |
| LS-21474 |
| LS-61218 |
| MCULE-1576765478 |
| MCULE-3200317958 |
| MolPort-003-983-404 |
| N-Methylnorapomorphine hydrochloride |
| N21FAR7B4S |
| NCGC00025349-01 |
| NCGC00025349-02 |
| NCGC00025349-03 |
| NCGC00025349-04 |
| NCGC00025349-05 |
| NH001 |
| NSC 11442 |
| NSC-11442 |
| NSC11442 |
| PDSP1_000780 |
| PDSP2_001488 |
| pomorphini hydrochloridum |
| Prestwick_28 |
| Prestwick0_000101 |
| Prestwick1_000101 |
| Prestwick2_000101 |
| Prestwick3_000101 |
| Q-200645 |
| R-(-)-Apomorphine |
| R-(-)-apomorphine HCl |
| R-(-)-Apomorphine hydrochloride |
| R( C)-10,11- paragraph signthornoC>>u degrees centAEO.E |
| R( C)-APO |
| SCHEMBL8524 |
| SCHEMBL8541 |
| SKYZYDSNJIOXRL-BTQNPOSSSA-N |
| SMP1_000027 |
| SPBio_002021 |
| SR-01000597777 |
| SR-01000597777-1 |
| Tocris-2073 |
| Tox21_110967 |
| Tox21_110967_1 |
| UNII-9K13MD7A0D |
| UNII-N21FAR7B4S |
| Uprima |
| Uprima (TN) |
| VMWNQDUVQKEIOC-CYBMUJFWSA-N |
| VR-040 |
| VR-400 |
| VR004 |
| WLN: T C6666 1A Q KN & TT & J DQ EQ K1 & GH |
| ZINC9073 |
US Patents and Regulatory Information for apomorphine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Us Worldmeds | APOKYN | apomorphine hydrochloride | INJECTABLE;SUBCUTANEOUS | 021264-002 | Apr 20, 2004 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Us Worldmeds | APOKYN | apomorphine hydrochloride | INJECTABLE;SUBCUTANEOUS | 021264-001 | Apr 20, 2004 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.